
August 02, 2016 - 02:00 pm - 00:00 am
Bad Homburg, Germany
Conference Call Q2 2016, Fresenius
Live Webcast

May 13, 2016 - 10:00 am - 00:00 am
Frankfurt, Germany
Annual General Meeting 2016, Fresenius
Webcast (Replay) of CEO Ulf Mark Schneider's speech
Information and documents
Fresenius has put its new website online: www.fresenius.com. The relaunched website combines technology and design in a modern, user-friendly Internet format. The content has been updated and rearranged, with easy-to-use navigation. Powerful photographs on the homepage will guide visitors to interesting topics. The responsive design optimizes the display of all content on mobile devices and ensures quick loading times.
Under the “Stories” menu point, visitors can learn more about Fresenius’ patients, employees, business locations and operations. The stories are not only about facts, figures and business results, but tell a broader public about the company’s values and aspirations.
Patients, investors and journalists will find other relevant information presented in dedicated chapters. A new feature for journalists and other media representatives is the “Media Center” page, where Fresenius is providing photographs, videos and other materials for editorial use.
Job seekers and applicants can find all the information they need about Fresenius as an employer, along with job postings and additional services, under the Fresenius Careers website, which has also been relaunched. www.career.fresenius.com now features a new, responsive design, embedded social media channels, and an improved menu structure and user interface.
The application process has been simplified. Job candidates can now execute the entire process – from checking for openings to completing an application – on their tablet or smartphone.
December 03, 2015
Boca Raton, USA
Bank of America Merrill Lynch – Leveraged Finance Conference
December 2 – 4, 2015
Moody’s Investors Service has upgraded the corporate credit rating of Fresenius from Ba1 to Baa3 with a stable outlook.
The upgrade reflects Moody's view that Fresenius' business profile has improved over the last years supported by higher business and geographical diversification and increased scale as well as a strong track record of profitable growth and deleveraging post acquisitions.
In January 2015, Standard & Poor’s upgraded the corporate credit rating of Fresenius from previously BB+ to BBB- with a stable outlook.
Fresenius continues to view itself as an active consolidator in its markets and will continue to focus on financing acquisitions primarily with debt.
This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements in this release.
Moody’s Investors Service has upgraded the corporate credit rating of Fresenius from Ba1 to Baa3 with a stable outlook.
The upgrade reflects Moody's view that Fresenius' business profile has improved over the last years supported by higher business and geographical diversification and increased scale as well as a strong track record of profitable growth and deleveraging post acquisitions.
In January 2015, Standard & Poor’s upgraded the corporate credit rating of Fresenius from previously BB+ to BBB- with a stable outlook.
Fresenius continues to view itself as an active consolidator in its markets and will continue to focus on financing acquisitions primarily with debt.
This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements in this release.